Regimen Reference Order LYMP – R-ICE (SUBCUTANEOUS Injection or RAPID IV riTUXimab)

ARIA: LYMP – [R-ICE (SUBCUT @ Cycle #1)]

Planned Course:Every 21 days up to 6 cyclesIndication for Use:Relapsed/Refractory Non-Hodgkin Lymphoma

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than 1×10^9 /L AND Platelets equal to or greater than 75 x 10^9 /L

Contact Hematologist if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements			
Drug	Dose CCMB Administration Guideline		
Instruct patient to start vigorous oral pre-hydration (600-900 mL) the morning of ifosfamide treatment (Self-administered at home)			
allopurinol*	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles (Self-administered at home)	
		*Only patients at risk of tumor lysis syndrome will be prescribed allopurinol	

LYMI	P – R-ICE (SUBCU	Treatment TANEOUS Ir	Regimen njection or RAPID IV riTUXimab)
Establish primary s	olution 500 mL of: nor	mal saline	
Drug	Hours of Administration	Dose	CCMB Administration Guideline
Day 1 – riTUXima	b SUBCUTANEOUS In	jection	
cetirizine	Minus 1 hours and 50 minutes	10 mg	Orally 30 minutes prior to riTUXimab
acetaminophen	minus 1 hours and 50 minutes	650 mg	Orally 30 minutes prior to riTUXimab
dexamethasone	minus 1 hour and 50 minutes	12 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes af	ter completion of IV pr	e-medication(s) l	before starting riTUXimab
riTUXimab (Subcutaneous)	minus 1 hour and 20 minutes	1400 mg (1400 mg = 11.7 mL)	Subcutaneous: Administer over 5 minutes into abdomen Syringe should be held in hand for 5 minutes to warm up and decrease viscosity

•	D 1		-
А	υ	JL	

		Use 25G needle
		*Alert: rapid infusion and subcutaneous route not to be used for riTUXimab naïve patients
		*Nursing Alert: Ensure subcutaneous riTUXimab formulation is used (riTUXimab-hyaluronidase, human)
minus 1 hour and 15 minutes	500 mL	IV over 1 hour (Pre hydration)
minus 30 minutes	16 mg	Orally 30 minutes pre-chemotherapy
minus 15 minutes	333 mg/m ²	IV in normal saline 50 mL over 15 minutes Immediately prior to ifosfamide
Hour 0	1667 mg/m ²	IV in normal saline 250 mL over 1 hour
Hour 1	AUC 5 mg/mL.min; maximum dose 750 mg (see table below)	IV in D5W 250 mL over 30 minutes
Hour 1 and 30 minutes	100 mg/m ²	IV in normal saline 500 mL over 1 hour Use non-DEHP bags and non-DEHP administration sets
Hour 2 and 30 minutes	500 mL	IV over 90 minutes (Post hydration)
Hour 4	333 mg/m ²	IV in normal saline 50 mL over 15 minutes
Hour 6	666 mg/m ²	Orally with juice or soft drink (Self-administered at home) *Nursing alert: Inform patient time to take dose
•	OR	
Rapid INTRAVENOU	S Infusion	
Minus 3 hours and 15 minutes	10 mg	Orally 30 minutes prior to riTUXimab
minus 3 hours and 15 minutes	650 mg	Orally 30 minutes prior to riTUXimab
minus 3 hours and 15 minutes	12 mg	IV in normal saline 50 mL over 15 minutes
er completion of IV pr	e-medication(s) k	pefore starting riTUXimab
minus 2 hours and 45 minutes	375 mg/m ²	Rapid infusion:IV in normal saline over 90 minutesInfuse 50 mL of a 250 mL bag (100 mL of a 500 mL bag)of the dose over 30 minutes, then infuse theremaining 200 mL (or 400 mL of a 500 mL bag) over 60minutes*Alert: Ensure brand name on prescription label
	15 minutes minus 30 minutes minus 15 minutes Hour 0 Hour 1 Hour 1 Hour 1 and 30 minutes Hour 2 and 30 minutes Hour 4 Hour 6 Rapid INTRAVENOU Minus 3 hours and 15 minutes minus 3 hours and 15 minutes minus 3 hours and 15 minutes er completion of IV pro minus 2 hours and	15 minutes16 mgminus 30 minutes16 mgminus 15 minutes333 mg/m²Hour 01667 mg/m²Hour 1AUC 5 mg/mL.min; maximum dose 750 mg (see table below)Hour 1 and 30 minutes100 mg/m²Hour 2 and 30 minutes500 mLHour 4333 mg/m²Hour 6666 mg/m²OFRapid INTRAVENOUS InfusionMinus 3 hours and 15 minutes10 mg10 mgsinutes10 mgminus 3 hours and 15 minutes650 mgminus 3 hours and 15 minutes12 mger completion of IV pre-medication(s) Iminus 2 hours and 375 mg/m²

ADULT	

		71	1
			prescribed order Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability *Alert: rapid infusion and subcutaneous route not to be used for riTUXimab naïve patients *Alert: Pharmacy to ensure final volume on label
normal saline	minus 1 hour and 15 minutes	500 mL	IV over 1 hour (Pre hydration)
ondansetron	minus 30 minutes	16 mg	Orally 30 minutes pre-chemotherapy
mesna	minus 15 minutes	333 mg/m ² IV in normal saline 50 mL over 15 minutes Immediately prior to ifosfamide	
ifosfamide	Hour 0	1667 mg/m ²	IV in normal saline 250 mL over 1 hour
CARBOplatin	Hour 1	AUC 5 mg/mL.min; maximum dose 750 mg (see table below)	IV in D5W 250 mL over 30 minutes
etoposide	Hour 1 and 30 minutes	100 mg/m ²	IV in normal saline 500 mL over 1 hour Use non-DEHP bags and non-DEHP administration sets
normal saline	Hour 2 and 30 minutes	500 mL	IV over 90 minutes (Post hydration)
mesna	Hour 4	333 mg/m ²	IV in normal saline 50 mL over 15 minutes
mesna	Hour 6	666 mg/m ² Orally with juice or soft drink (Self-administered at home) *Nursing alert: Inform patient time to take do	
Days 2 and 3			
normal saline	minus 1 hour and 15 minutes	500 mL	IV over 1 hour (Pre hydration)
ondansetron	minus 30 minutes	16 mg Orally 30 minutes pre-chemotherapy	
dexamethasone	minus 30 minutes	12 mg Orally 30 minutes pre-chemotherapy	
mesna	minus 15 minutes	333 mg/m² IV in normal saline 50 mL over 15 minutes Immediately prior to ifosfamide	
ifosfamide	Hour 0	1667 mg/m ²	IV in normal saline 250 mL over 1 hour
etoposide	Hour 1	100 mg/m ²	IV in normal saline 500 mL over 1 hour Use non-DEHP bags and non-DEHP administration sets
normal saline	Hour 2	500 mL	IV over 2 hours (Post hydration)
mesna	Hour 4	333 mg/m ²	IV in normal saline 50 mL over 15 minutes
mesna	Hour 6	666 mg/m ²	Orally with juice or soft drink



(Self-administered at home)
*Nursing alert: Inform patient time to take dose

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See LYMP DSG – Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

• CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

INTRAVENOUS riTUXimab

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

SUBCUTANEOUS riTUXimab

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline, <u>at discharge</u> and as clinically indicated
- 15 minute observation period required after each dose

Recommended Support Medications			
Drug Dose		CCMB Administration Guideline	
pegfilgrastim (brand name specific) (See Filgrastim Clinical Guide)	6 mg	Subcutaneous once on Day 6 *Alert: pegfilgrastim to be given as a single dose once per chemotherapy cycle no sooner than 24 hours after chemotherapy	
dexamethasone	8 mg	Orally once daily on Days 4 and 5	
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting	

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to:
 - Self-administer "Hour 6" of mesna by mixing the contents of the mesna syringe in juice (not grapefruit) or soft drink. If patient vomits within 2 hours of taking "Hour 6" mesna, they should be advised to contact their cancer team. Patient may require intravenous hydration
 - Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
 - Continue taking anti-emetic(s) at home
 - Report changes in mental status; ifosfamide can cause encephalopathy (rare)
 - Maintain oral intake of 2000 mL (8 glasses) of fluid daily at home
 - o Empty bladder every 2 hours while awake and at bedtime for 24 hours after each dose of ifosfamide
 - Obtain immediate assistance as per your clinic's contact instructions if:
 - Symptoms of hemorrhagic cystitis (e.g. dysuria, hematuria)
 - Unable to drink recommended amount of fluid



Please refer to CCMB Formulary for Criteria for Use


Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion
 of chemotherapy

ADDITIONAL INFORMATION

- Administering nurse must document any infusion-related reactions with any dose of riTUXimab
- Ensure there were **no Grade 3 or 4** infusion-related reactions with any previous dose prior to administering riTUXimab via subcutaneous injection or rapid infusion
- Intravenous riTUXimab formulation is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after riTUXimab. Ensure prescription label matches the brand name on prescribed order for intravenous riTUXimab
- CARBOplatin dose considerations:
 - o CCMB Lymphoproliferative DSG uses actual body weight to calculate GFR
 - CCMB Lymphoproliferative DSG uses a maximum CARBOplatin dose of 750 mg for this regimen
 - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the prescriber

CARBOplatin Dosing Calculations per CCMB Lymphoproliferative DSG

Calculation of CARBOplatin dose: (max.750 mg)



AUC= Area Under Curve

• The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation above may not be appropriate for some patient populations (for example, acute renal failure)

